Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
At least a 1-year history of chronic migraine (CM) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), 2018
Age of the participant at the time of migraine onset < 50 years
Confirmation of headache/migraine headache day frequency as follows:
Participants must be using a medically acceptable and effective method of birth control during the course of the entire study
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
778 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal